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Introduction 
 
 
The discovery of microRNAs 
In the past years the scientific community was focused mainly on the study 
of protein coding genes as important players in the pathogenesis of cancer. 
Little interest has been offered to non-coding RNA genes (ncRNA), 
heterogeneous class of genes that are transcribed to RNA but not translated 
to protein. Thirteen years ago a genetic screen in C. Elegans, studied to 
identify genes involved in development timing, resulted in the discovery of 
the first microRNA (miRNA), lin-4, which subsequently was found to 
interact with the 3’ untraslated region of Lin-14 messenger RNA and to 
repress its translation. This fashinating form of gene regulation was ignored 
even during the era of complete genome sequencing, since almost all means 
of gene identification assume that gene encodes protein. 
Seven years later, the second RNA of the miRNAs class, let-7, emerged 
from another C. Elegans genetic screen. The discovery of let-7 was 
particularly exciting, because its phylogenetic conservation in metazoans 
implied that miRNAs represented a novel fundamental regulatory class of 
genes. The discovery of miRNAs coincided in an era in which genetic and 
mechanistic studies started to unveil the mechanism of small interfering 
RNA (siRNA), and the connection between the two pathways was soon 
made. 
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The understanding of the miRNAs structure fuelled the development of 
efficient cloning strategies that isolated dozens of miRNAs from diverse 
eukaryotic species. Meanwhile, many genome projects were completed and 
the annotated genomes were used to predict miRNAs based on their known 
features using bioinformatics approaches. 
 
Genomics of microRNAs 
Today the miRNA database miRBase (www.sanger.com) contains 4039 
miRNA entries from 38 species. 
The large number of verified and predicted miRNAs immediately created a 
new challenge. 
Almost 50% of mammalian microRNAs are located in introns of protein 
coding genes or long ncRNAs transcripts, whereas the remaining part is 
considerable as indipendent transcription units with specific promoter core 
elements and polyadenilation signals [for review see(1-3)]. Among the 
intragenic miRNAs, 40% are found in introns of protein coding genes, 
whereas ~10% are located in introns of long ncRNA transcripts. The vast 
majority of miRNA clusters are single transcription units or overlapped in 
the same host transcripts, within exons or introns, and in some cases 
depending on alternative splicing of the host gene, implying that they are 
transcribed as polycistronic transcripts. Additionally, many miRNAs overlap 
with two or more transcription units transcribed on opposite DNA strands.  
The analysis of miRNAs genomic loci evidences that host genes encoding 
proteins are involved in a broad spectrum of biological function ranging 
from embryonic development to the cell cycle and physiology. In addition to 
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the miRNAs located in protein coding genes, a large group of microRNAs 
resides in transcripts that lack a significant protein-coding potential, 
classified as long ncRNAs. These types of ncRNA transcripts are sometimes 
referred to as mRNA-like ncRNAs (mlncRNA) because they are spliced, 
polyadenilated and also spatio-temporally expressed. Deleted in Leukemia 2 
(DLEU2) and BIC are host-genes mlncRNAs respectively for miR-15/miR-
16 cluster and miR-155 (4, 5). 
microRNAs Transcription and Maturation 
Initially, the researchers believed that microRNAs were transcribed by RNA 
polymerase III like other small RNAs, as some as tRNAs. However, 
numerous evidences supported the possibility of a transcription mediated by 
RNA polymerase II. In 2004, three direct evidences have been reported to 
evaluate the strict correlation between microRNAs and pol II: (i) the 
miRNAs transcripts are capped and polyadenilated; (ii) the transcription of 
miRNAs transcripts is sensitive to alpha-amanitine at the specific 
concentration for pol II inhibition; (iii) the promoter region, responsible for 
miRNA transcription, is associated to pol II complex (1). Animal 
microRNAs are identified as part of 80 nt RNA with stem-loop structure 
(pre-miRNA) that are included in several hundreds/thousands nucleotide 
long miRNAs precursors, named primary miRNAs precursor (pri-miRNA) 
(Figure 1). The production of microRNAs from pri-miRNA to mature miR is 
a complex and coordinated process where different groups of enzymes and 
associated proteins, located in the nucleus or cytoplasm, operate the 
multistep maturation of these tiny RNAs. Principally, the maturation process 
of microRNAs can be resumed in three important steps: cropping, export 
and dicing. 
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In the cropping, the pri-miRNA is converted in pre-miRNA through the 
cleavage activity of Drosha enzyme, a nuclear Ribonuclease III 
endonuclease capable to crop the flank regions of pri-miRNA in turn to 
liberate the 60-70 nt pre-miRNA (6). Different pri-miRNA requisitions are 
necessary to obtain an efficient precursor maturation by Drosha: first, a large 
terminal loop (> 10 nucleotides) in the hairpin and a stem region one turn 
bigger than the pre-miRNA; second, a 5’ and 3’ single stranded RNA 
extension at the base of the future microRNAs [for review see (7, 8)]. 
 
Figure 1  
The pri-miRNA is converted in pre-miRNA through the cleavage activity of Drosha 
enzyme. The resulting product of cropping, the pre-miRNA, presents a 5’ phosphate and 
3’ hydroxy termini. The produced pre-miRNA is exported to the cytoplasm by Exportin-
5/RnaGTP. Exp-5 forms a nuclear heterotrimer with RanGTP and pre-miRNA, resulted 
from Drosha processing. This interaction, which is dependent on RNA structure but 
independent of sequence, stabilizes the nuclear pre-miRNA and promotes the export to 
the cytoplasm. 
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It has been proposed that Drosha may recognize the primary precursor 
through the stem-loop structure and then cleave the stem at a fixed distance 
from the loop to liberate the pre-miRNA. 
 
How the enzyme is capable to discriminate the pri-miRNA stem-loop 
structure in respect to the others stem-loop cellular RNAs is not clear, but 
probably proteins associated with Drosha confer specificity to this process. 
In fact, Drosha has been found as a part of large protein complex of 
~650kDa, which is known as the “Microprocessor”, where Drosha interacts 
with its cofactor, the Di George syndrome critical region gene 8 (DGCR8) 
protein in human and Pasha in Drosophila melanogaster (9). 
The Microprocessor appears to represent a heterotetramer consisting of two 
Drosha and two DGCR8 molecules; because DGCR8 contains two 
consensus dsRNA binding domain, this protein may play an important role 
in the substrate discrimination and binding.  
 
The resulting product of cropping, the pre-miRNA, presents a 5’ phosphate 
and 3’ hydroxy termini, and two or three nucleotides single-stranded 
overhanging ends, classic characteristics of Rnase III cleavage of dsRNAs. 
After the Microprocessor nuclear activity, the produced pre-miRNA is 
exported to the cytoplasm by Exportin-5/RnaGTP  (10). 
Exp-5 forms a nuclear heterotrimer with RanGTP and pre-miRNA, resulted 
from Drosha processing. This interaction, which is dependent on RNA 
structure but independent of sequence, stabilizes the nuclear pre-miRNA and 
promotes the export to the cytoplasm. In any export, once the Exp5-
 8 
RanGTP-pre-miRNA complex has reached the cytoplasm through the 
nuclear pore, the RnaGTP is hydrolyzed to RanGDP and the pre-miRNA is 
released.  
 
Arrived into the cytoplasm, the pre-miRNA is processed in 18~22 
nucleotides miR duplexes by the cytoplasmic Rnase III Dicer and, in 
humans, its partner TRBP. The PAZ domain of Dicer is thought to interact 
with the nucleotides 3’ overhang present in the pre-miRNA hairpin while the 
dsRNA binding domain binds the stem and defines the distance of cleavage 
from the base of pre-miRNA.  The cleavage 22nt-long miRNA duplexes 
have a reduced half-life. Normally, one strand of this duplex is degraded 
whereas the other strand accumulates as a mature miRNA.  
 
microRNA in action: RISC and gene target inhibition 
In the RNA duplex produced from the Dicer activity, the mature miRNA is 
only partially paired to the miRNA, the small RNA that resides on the 
opposite pre-miRNA stem. From the miRNA-miRNA duplex, only the 
miRNA enters preferentially in the protein effector complex, the RNA 
Induced Silencing Complex (RISC) or miRNAsC or miRgonaute, which 
mediates the degradation or translation inhibition of mRNAs target gene 
(Figure 2) (11).  
Several proteins have identified as essential components of RISC, but only a 
few have been functionally characterized in the post-translational regulation. 
The core component of every RISC is a member of the Argonaute (Ago) 
protein family, whose members present a central PAZ domain like Dicer and 
a carboxy terminal PIWI domain. This domain binds the miR/miR duplex to 
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the 5’ end whereas the PAZ domain binds to the 3’ end of singled-strand 
RNAs; moreover, structural and biochemical studies have suggested that the  
 
 
Figure 2 
1-Plasmid-expressed short hairpin (shRNA) requires the activity of endogenus Exportin-5 
for nuclear export (1). 
2-Ago2 (Argonaute 2) is recruited by TRBP (2) that forms a dimer with Dicer (3) and 
than receives the shRNA  (4-6). 
3-The shRNA is cleaved in one step by Dicer generating a 19-23 nt duplex siRNA with 2 
nt 3’ overhangs. 
4-After identification of the “guide strand” in the siRNA duplex, the “passenger strand” 
is cleaved by Ago2 (4). 
5-The “guide strand” is released. 
6- The “guide strand” is integrated in the active RNA Interference  Specificity Complex 
(RISC) that contains different argonautes  and argonaute-associated proteins (7). 
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Ago proteins are the target-cleaving endonuclease of RISC and in this 
activity the complex is helped and coordinated by other proteins whose 
function is not really understood like RNA-binding protein VIG, the Fragile-
X related protein in Drosophila, the exonuclease Tudor-SN and many other 
putative helicases (12). 
In the human cells, after the microRNAs transfection by vectors or miRNA 
precursors, and the following activation of RISC activity, the core 
component of RISC, together with the triggering miRNA target mRNA, is 
concentrated in cytoplasmic foci known as Processing bodies (P-bodies) or 
GW-bodies. According with this triggered RISC localization, the researchers 
thought that the microRNAs, in association with AGO proteins, might be 
capable to repress the translation at ribosomal level and to re-localize  
mRNA targets to the P-bodies (Figure 3) (13).  
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Figure 3  
Post-transcriptional processes have a central role in the regulation of eukaryotic gene 
expression. Although it has been known for a long time that these processes are 
functionally linked, often by the use of common protein factors, it has only recently 
become apparent that many of these processes are also physically connected. Indeed, 
proteins that are involved in mRNA degradation, translational repression, mRNA 
surveillance and RNA-mediated gene silencing, together with their mRNA targets, 
colocalize within discrete cytoplasmic domains known as P bodies. The available 
evidence indicates that P bodies are sites where mRNAs that are not being translated 
accumulate, the information carried by associated proteins and regulatory RNAs is 
integrated, and their fate — either translation, silencing or decay — is decided. 
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microRNAS: function in normal and disease states 
 
How do miRNAs work and what genes do they regulate? Expression 
profiling and functional studies suggest that miRNAs play a key role in 
biology, having been associated not only with physiological, but also with 
pathological processes such as cancer. 
In lower species, miRs are involved in a variety of basic processes, e.g., cell 
proliferation and apoptosis (14, 15), neuronal development (16), fat 
metabolism (17) and stress response (18). In some studies, key target 
mRNAs have been identified but relatively little is known of the functional 
role of miRNAs in mammalian species. We do know, however, that miR-
181 is involved in the control of lymphopoiesis (19) miR-375 regulates 
insulin secretion by targeting myotrophin mRNA (20), and the miR-let7 
family may plays a role in oncogenesis via RAS oncogene mRNAs (21). 
Furthermore, enforced expression of the miR-17-92 cluster from 
chromosome 13q32-33 in conjunction with c-myc accelerates tumor 
development in a mouse B-cell lymphoma model (22). 
Two microRNAs from the same cluster, miR-17-5p and miR-20a negatively 
regulates the E2F1 transcription factor, a gene proved to function as a tumor 
suppressor in some experimental systems (23). 
miR-15a and miR-16-1 are deleted or down-regulated in the majority of 
chronic lymphocytic leukemia (24). Functional studies indicated that miR-
221&222 inhibit normal erythropoiesis and erythroleukemic cell growth at 
least in part via Kit receptor down-modulation, (25) and their ectopic 
overexpression directly results in p27Kip1 down-regulation in aggressive 
prostate  (26). 
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Apotosis: extrinsic and intrinsic pathway 
Lung tumors are among the most deadly types of cancer. Advances in 
standard treatments for this tumor, such as surgery, radiotherapy, and 
chemotherapy, have not significantly increased patient survival. One of the 
most important issues that affects survival rate is resistance to therapeutic 
drugs. Only 20-30% of treated NSCLC patients have clinical evidence of a 
response. Therefore, the development of new therapeutic strategies is 
necessary for the treatment of this type of cancer. 
The Apo2L/TNF-α-related apoptosis-inducing ligand (TRAIL) is a relatively 
new member of the TNF family known to induce apoptosis in a variety of 
cancers (27). Apoptosis represents a tightly regulated and evolutionarily 
conserved program of cell suicide which is involved in normal cellular 
homeostasis (28).  
Most chemotherapeutic drugs kill cancer cells by inducing apoptosis, and 
many similarities exist in cellular response to drug-induced apoptosis, 
regardless of their primary target (14, 29-37). Apoptosis, from the Greek 
word for “falling off ” or “dropping off” (as leaves from a tree), is defined 
by distinct morphological and biochemical changes mediated by a family of 
cysteine aspartic acid-specific proteases (caspases), which are expressed as 
inactive precursors or zymogens (pro-caspases) and are proteolytically 
processed to an active state following an apoptotic stimulus. To date, 
approximately 14 mammalian caspases have been identified and can be 
roughly divided into three functional groups: apoptosis initiator (including 
caspase-2, -9, -8, -10), apoptosis effector (including caspase-3, -6, -7), and 
cytokine maturation (including caspase-1,-4,-5,-11,-12,-13,-14)(38-40). .  
Two separable pathways lead to caspases activation: the extrinsic pathway 
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and the intrinsic pathway (Figure 2). The extrinsic pathway is initiated by 
ligation of transmembrane death receptors (Fas, TNF receptor, and TRAIL 
receptor) with their respective ligands (FasL, TNF, and TRAIL) to activate 
membrane-proximal caspases (caspase-8 and –10), which in turn cleave and 
activate effector caspases such as caspase-3 and –7. 
The intrinsic pathway requires disruption of the mitochondrial membrane 
and the release of mitochondrial proteins, such as cytochrome c. 
Cytochrome c, released from the mitochondrial intermembrane space to 
cytoplasm, works together with the other two cytosolic protein factors, 
Apaf-1 (apoptoic protease activating factor-1) and procaspase-9, to promote 
the assembly of a caspase-activating complex termed the apoptosome, which 
in return induces activation of caspase-9 and thereby initiates the apoptotic 
caspase cascade (39-43).  
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Figure 4 
Known as the "death receptor pathway" the extrinsic or caspase 8/10 dependent pathway 
is activated by ligand binding. The "death receptors" are specialized cell-surface 
receptors including Fas/CD95, tumor necrosis factor-alpha (TNF-alpha) receptor 1, and 
two receptors, DR4 and DR5, that bind to the TNF-alpha related apoptosis-inducing 
ligand (TRAIL). The extrinsic and intrinsic pathways unite in the activation of Caspase-3, 
though the two pathways communicate through the pro-apoptotic Bcl-2 family member 
Bid before uniting at the shared activation of Caspase-3. 
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The primary regulatory step for mitochondrial-mediated caspase activation 
(the intrinsic pathway) might be at the level of cytochrome c release (42, 
43). T he known regulators of cytochrome c release are Bcl-2 family 
proteins (41-45). 
A ccording to their function in apoptosis, the mammalian Bcl-2 family can 
be divided into pro-apoptotic and anti-apoptotic members. The pro-apoptotic 
members include Bax, Bcl-Xs, Bak, Bok/Mtd, which contain 2 or 3 Bcl-2 
homology (BH) regions, and molecules such as Bad, Bik/Nbk, Bid, 
Hrk/DP5, Bim/Bod, and Blk, which contains only the BH3 region. The anti-
apoptotic Bcl-2 family members include Bcl-2, Bcl-XL, Bcl-w, A1/Bfl-1, 
Mcl-1, and Boo/Diva, which contain three or four regions with extensive 
aminoacid sequence similarity to Bcl-2 (BH1-BH4) (45). Overexpression 
of the anti-apoptotic molecules such as Bcl-2 or Bcl-XL blocks cytochrome 
c release in response to a variety of apoptotic stimuli. On the contrary, the 
pro-apoptotic members of the Bcl-2 family proteins (such as Bax and Bid) 
promote cytochrome c release from the mitochondria. Pro-apoptotic and 
anti-apoptotic members of the Bcl-2 protein family can physically interact. 
For example, binding of BH-3 only proteins (e.g., Noxa, Puma, Bad, and 
Bim) to anti-apoptotic Bcl-2 proteins (e.g., Bcl-2 and Bcl-XL) results in 
activation of Bax and Bak (44, 45). In addition, there is considerable cross-
talk between the extrinsic and intrinsic pathways. For example, caspase-8 
can proteolytically activate Bid, which can then facilitate the release of 
cytochrome c and amplifies the apoptotic signal following death receptor 
activation. (36, 39-43). 
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TRAIL and miRs 
Most of the anticancer agents either directly induce DNA damage or 
indirectly induce secondary stress-responsive signaling pathways to trigger 
apoptosis by activation of the intrinsic apoptotic pathway, and some can 
simultaneously activate the extrinsic receptor pathway. Therefore, molecules 
or signaling events that regulate the processes of apoptosis can also affect 
cellular response to drugs. 
TRAIL (TNF-related apoptosis-inducing ligand, also called APO-2) is a 
protein consisting of 281 amino acids that  can bind to five receptors (Fig. 5) 
of which four are located at the cell surface: TRAIL-R1 (DR4), TRAIL- R2 
(DR5), TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2). Only two of these 
receptors, R1 and R2, contain a functional cytoplasmic death domain motif 
and are capable of delivering the apoptotic signal of TRAIL by association 
of the death domain with the Fas-associated death domain protein (FADD), 
containing the death effector domain, which is involved in the activation of 
caspase-8 (46). 
The other two receptors, DcR1 and DcR2, are “decoy receptors” and lack 
the ability to initiate the apoptotic cascade. 
Treatment with TRAIL induces programmed cell death in a wide range of 
transformed cells, both in vitro and in vivo, without producing significant 
effects in normal cells (27, 46). This unique property makes TRAIL an 
attractive candidate for cancer therapy. Preclinical experiments in mice and 
nonhuman primates have shown that administration of TRAIL suppresses 
tumor growth without apparent systemic cytotoxicity (47, 48). Therefore, 
TRAIL represents a promising anti-cancer agent. 
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Figure 5  
Schematic drawing of TRAIL receptors, which can be divided into two categories: 
Death receptors:  TRAIL-R1 and TRAIL-R2 contain the death domain, capable of  
delivering the apoptotic signal of TRAIL by association of the death domain with FADD, 
containing the death effector domain, which is involved in the activation of caspase-8 
Decoy receptors:  TRAIL-R3 and TRAIL-R5  lack the death domain while TRAIL-R4 
contains a truncated non-functional death domain.  These three receptors can bind to 
TRAIL, but cannot induce apoptosis.  TRAIL-R5 is secreted to the extracellular fluid.  
All other receptors are transmembrane proteins. 
 
 
However, a significant proportion of human cancer cells are resistant to 
TRAIL-induced apoptosis, and the mechanism of sensitization seems to 
differ among cell types. 
Different studies relate resistance to TRAIL-induced cell death to 
downstream factors. It has been shown that down-regulation of PED or 
cellular FLICE-like inhibitory protein (c-Flip) can sensitize cells to TRAIL-
induced apoptosis (47, 48). However the mechanism of TRAIL resistance is 
still largely unknown. 
 19 
In this study, in order to identify novel mechanisms implicated in TRAIL 
resistance, we performed a genome-wide expression profiling of miRs in 
four different cell lines in human non small cell lung cancer (NSCLC).  
We found that miR-221&222 are markedly up-regulated in TRAIL-resistant, 
and down-regulated in TRAIL-sensitive, NSCLC cells. Our experiments 
indicate that miR-221&222 modulate TRAIL sensitivity in lung cancer cells 
mainly by modulating p27kip1 expression and TRAIL-induced caspase 
machinery. 
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 Figure 6 
 
Members of the tumor necrosis factor (TNF) super family of receptors induce apoptosis 
by recruiting adaptor molecules through death domain interactions. 
The central adaptor molecule for these receptors is the death domain-containing protein 
FADD. FADD binds a death domain on a receptor or additional adaptor and recruits 
caspases to the activated receptor. FADD,caspases-8 and caspase-10 are recruited to the  
DISC, “death-inducing signalling complex”. DISC formation leads to activation of a 
protease cascade, finally resulting in cell death. The TRAIL death receptor-mediated 
“extrinsic” pathway and the “intrinsic” pathway, which is controlled by the interaction of 
members of the Bcl-2 family, interact with each other in the decision about life or death 
of a cell. Apoptotic and non-apoptotic signalling is influenced by the NF-κB, PKB/Akt 
and the MAPK signalling pathways. 
The control of cell survival and death is through NF- B–JNK cross-talk. Positive 
feedback loops exist between  caspases and JNK. Negative feedback loops exist between 
NF- B and caspases. NF-B functions as a pro-survival transcription factor by inducing 
the expression of antiapoptotic genes, such as the Bcl-2 family members and caspase 
inhibitors. Activation of NF- B also results in inhibition of prolonged JNK activation, 
mostly through inhibition of ROS accumulation.  
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Experimental Procedures 
 
Materials- Media, sera and antibiotics for cell culture were from Life 
Technologies, Inc. (Grand Island, NY, USA). Protein electrophoresis 
reagents were from Bio-Rad (Richmond, VA, USA) and Western blotting 
and ECL reagents from GE Health care. All other chemicals were from 
Sigma (St. Louis, MO, USA).  
 
Cell culture- Human CALU-1 and A549 NSCLC cell lines were grown in 
DMEM containing 10% heat-inactivated FBS and with 2mM L-glutamine 
and 100U/ml penicillin-streptomycin. H460 and A459 cell lines were grown 
in RPMI containing 10% heat-inactivated FBS and with 2mM L-glutamine 
and 100U/ml penicillin-streptomycin.   
 
Western blotting-  Total proteins from CALU-1, A459, A549 and H460 
cells were extracted with RIPA buffer (0,15mM NaCl, 0,05mM Tris-HCl, 
pH 7,5, 1% Triton, 0,1% SDS, 0.1% sodium deoxycolate and 1% Nonidet 
P40). 
Fifty µg of sample extract were resolved on 7.5-12% SDS-polyacrylamide 
gels using a mini-gel apparatus (Bio-Rad Laboratories, Richmond, CA) and 
transferred to Hybond-C extra nitrocellulose. Membranes were blocked for 
1hr with 5% non-fat dry milk in TBS containing 0.05% Tween-20, incubated 
for 2h with primary antibody, washed and incubated with secondary 
antibody, and visualized by chemiluminescence. The following primary 
antibodies were used: Kit (R&D System), and a secondary anti-goat IgG 
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antibody peroxidase coniugate (Chemicon); anti-TRAIL-R1, -R2, -R3, and -
R4 (Santa Cruz,Inc.), anti-p27 kip1 (Santa Cruz, Inc), anti-caspase 8 (Cell 
Signaling), anti-caspase 3  and anti-PARP (Santa Cruz,Inc), anti-β-actin 
antibody (Sigma). Expression levels were analyzed with SCION IMAGE. 
 
FACS analysis- For flow cytometry analysis of cell surface Kit, cells were 
stained with primary anti-human h-SCFR affinity purified goat IgG or mouse 
MAb 002 (isotype control) (both from R&D Systems), followed by 
secondary antibody, Fluorescein conjugated goat F(ab’)2  (R&D Systems).  
 
Cell death and cell proliferation quantification- Cells were plated in 96-
well plates in triplicate and incubated at 37°C in a 5% CO2 incubator. Super-
Killer TRAIL (Alexis Biochemicals, Lausen, Switzerland) was used for 24-
48 hrs at 400 ng/ml. Cell viability was evaluated with the CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI), 
according to the manufacturer’s protocol. Metabolically active cells were 
detected by adding 20 µl of MTS to each well. After 2 h of incubation, the 
plates were analyzed in a Multilabel Counter (Bio-Rad, Richmond, VA, 
USA). Apoptosis was assessed using annexin V–FITC Apoptosis Detection 
Kits followed by flow cytometric analysis. Cells were seeded at 1.8 106 cells 
per 100-mm dish, grown overnight in 10% FBS/RPMI, washed with PBS, 
then treated for 24 hours with 200 ng TRAIL. Following incubation, cells 
were washed with cold PBS and removed from the plates by trypsinization. 
The resuspended cells were washed with cold PBS and stained with FITC-
conjugated annexin V antibody and propidium iodide (PI) according to the 
instructions provided by the manufacturer (Roche Applied Science, 
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Indianapolis, IN). Cells (50,000 per sample) were then subjected to flow 
cytometric analysis..The fraction of H460 cells treated with TRAIL was 
taken as the apoptotic cell population. The percentage of apoptosis indicated 
was corrected for background levels found in the corresponding untreated 
controls.  
 
RNA extraction, Northern blotting- Total RNA was extracted with TRIzol 
solution (Invitrogen) and the integrity of RNA was assessed with an Agilent 
BioAnalizer 2100 (Agilent, Palo Alto, CA). Northern blotting was 
performed as described in ref (4). Ten micrograms of total RNA from cell 
lines were loaded onto a precast 15% denaturing polyacrylamide gel (Bio-
Rad). The RNA was then electrophoretically transferred to bright-Star 
blotting membranes (Ambion). The oligonucleotides used as probes were the 
complementary sequences of the mature miRNA (miRNA registry): 
miR221, 5’-GAAACCCAGCAGACAATGTAGCT-3’; miR222, 
5’GAGACCCAGTAGCCAGATGTAGCT-3’. miR probes were end-labeled 
with [γ-32 P]-ATP by T4 polynucleotide kinase (USB,Cleveland). 
Prehybridization and hybridization were carried out in Ultrahyb Oligo 
solution (Ambion) containing 106 cpm/ml probes overnight 37˚C. The most 
stringent wash was with 2X SSC and 1% SDS  at 37˚C. For reuse, blots 
were stripped by boiling and reprobed. As a loading control U6 rRNA was 
used. The image of Northern hybridization signals was produced by using 
STORMSCANNER and IMAGEQUANT TL software (Molecular 
Dinamics) 
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miRNA Microarray experiments- 5 µg of total RNA from each sample 
was reverse transcribed using biotin end labeled random-octamer 
oligonucleotide primer.  
Hybridization of biotinlabeled complementary DNA was performed on a 
new Ohio State University custom miRNA microarray chip (OSU_CCC 
version 3.0), which contains 1150 miRNA probes, including 326 human and 
249 mouse miRNA genes, spotted in duplicates. The hybridized chips were 
washed and processed to detect biotin-containing transcripts by streptavidin-
Alexa647 conjugate and scanned on an Axon 4000B microarray scanner 
(Axon Instruments, Sunnyvale, Calif ). 
Raw data were normalized and analyzed in GENESPRING 7,2 software 
(zcomSilicon Genetics, Redwood City, CA). Expression data were median-
centered by using both the GENESPRING normalization option and the 
global median normalization of the BIOCONDUCTOR package 
(www.bioconductor.org) with similar results. Statistical comparisons were 
done by using the GENESPRING ANOVA tool, predictive analysis of 
microarray (PAM) and the significance analysis of microarray (SAM) 
software (http://www-stat.stanford.edu/~tibs/SAM/index.html). 
 
Real Time PCR- Real-time PCR was performed using a standard TaqMan 
PCR Kit protocol on an Applied Biosystems 7900HT Sequence Detection 
System (P/N: 4329002, Applied Biosystems). The 10 µl PCR reaction 
included 0.67 µl RT product, 1 µl TaqMan Universal PCR Master Mix (P/N: 
4324018, Applied Biosystems), 0.2 mM TaqMan probe,1.5 mM forward 
primer and 0.7 mM reverse primer. The reactions were incubated in a 96-
well plate at 95 ˚C for 10 min, followed by 40 cycles of 95 ˚C for 15 s and 
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60 ˚C for 1 min. All reactions were run in triplicate. The threshold cycle 
(CT) is defined as the fractional cycle number at which the fluorescence 
passes the fixed threshold. The comparative CT method for relative 
quantization of gene expression (User Bulletin #2, Applied Biosystems) was 
used to determine miRNA expression levels. Experiments were carried out 
in triplicate for each data point, and data analysis was performed by using 
software (BioRad). To normalize the expression levels of target genes, U6 
has been used.  
 
Bioinformatics- miR target prediction of the differentially expressed miRs 
was performed with TARGETSCAN, MIRANDA and PICTAR software. 
 
Pre-miRs and anti-miR miRNA inhibitors transfection in NSCLC cells- 
TRAIL sensitive cell lines (H460) were cultured to 80% confluence in p60 
plates with a serum-free medium without antibiotics and then transfected 
with 100 nmol of pre-miR-221 and 222 oligonucleotides or Negative 
Control for 48 hrs (Ambion). CALU-1 cells were cultured to 80% 
confluence in p60 plates with a serum-free medium without antibiotics. 100 
nmol of -221&222 anti miR miRNA inhibitors (Ambion) were transiently 
transfected in cells using LIPOFECTAMINE 2000 according to 
manufacturer’s instructions. Cells were incubated in the presence of the 
specific anti-miR miRNA inhibitors and Negative Control for 48 hrs. 
The Anti-miR miRNA Inhibitor Negative Control is a random sequence 
anti-miR molecule offered for use as a negative experimental control. The 
Anti-miR Negative Control has been extensively tested in many human cell 
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lines and tissues and validated to not produce any identifiable effect on 
known miRNAs function. 
Subsequently, TRAIL-induced cell death was analyzed as previously 
described.  
 
DNA demethylating agents and HDACis- TRAIL sensitive H460 cell line 
was treated with different concentrations of Trichostatin A (TSA) (100, 200, 
300, and 500 nM), sodium butyrate (10, 25, 50, and 75 mM) or 5’-Aza-2’-
deoxycytidine (1, 5, 10 mM). Moreover, we performed a time course with 
10mM 5’-Aza and 300nM TSA. Northern blotting were performed as 
previously described. 
 
Anti-p27Kip1 siRNA transfection in NSCLC- H460 cells were cultured to 
80% confluence and transiently transfected using LIPOFECTAMINE 2000 
with anti-p27kip1 siRNA (Santa Cruz) and anti- Kit siRNA (Dharmacon), a 
pool of 4 target specific 20-25 nt siRNAs designed to knock down gene 
expression. 20 nmol of p27kip1 RNA was transfected with 6µl transfection 
reagent, as described in the manufacturer’s protocol. 
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RESULTS 
 
 
The cytotoxic effects of TRAIL in human non small cell lung cancer 
(NSCLC)-  
We analyzed TRAIL sensitivity of different human NSCLC cell lines: A459, 
A549, CALU-1 and H460. Cells were exposed to TRAIL for 24 and 48 
hours (Figure 7A) after which cell death was assessed using an MTT assay 
or by FACS  with  annexin V and propidium iodide staining (data not 
shown).  As shown in Figure 7A, H460 cells underwent TRAIL-induced cell 
death whereas CALU-1 cells did not display sensitivity when exposed to 
soluble TRAIL; A459 and A549 cells showed an intermediate sensitivity. A 
possible mechanism of the differential sensitivity of the tested cells to 
TRAIL-induced apoptosis could be due to the variability of the cell surface 
levels of the death and decoy receptors resulting in increased apoptotic 
signaling in the sensitive cells. However, TRAIL receptor isoforms analyzed 
by western blot (Figure 7B) or FACS analysis (data not shown) revealed 
comparable levels of expression. Furthermore, although H460 cells do not 
express DcR1, the expression of DcR2 receptor is greater then CALU-1. 
Therefore, the expression of the decoy receptors within the two cell lines is 
balanced. 
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Figure 7 
(A) In order to assess TRAIL sensitivity, NSCLC cells were incubated  with Super-
Killer-TRAIL (400ng/ml) for 24 and 48 hours and viability evaluated as described in the 
methods section. Experiments were repeated four times in triplicate. H460 cells were 
more sensitive to TRAIL-induced apoptosis compared to CALU-1. A459 and A549 
exhibited an intermediate sensitivity. (B) TRAIL receptors expression in CALU-1 and 
H460 cells. Fifty micrograms of total extract was loaded onto 10% SDS-PAGE. The 
membrane was blotted with anti DR4, DR5 (1µg/ml) and DcR1 and DcR2 antibody (0.5 
µg/ml). Loading control was obtained with anti-β actin antibody (1:5000). 
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miRs expression screening in TRAIL resistant vs sensitive NSCLC cell 
lines-  
To investigate the involvement of miRs in TRAIL resistance, we analyzed 
the miRs expression profile in TRAIL-resistant (CALU-1) and semi-
resistant NSCLC cell lines (A459, A549) versus TRAIL sensitive cell line 
(H460). The analysis was performed with a microarray chip containing 1150 
miR probes, including 326 human and 249 mouse miRs, spotted in 
duplicates (49). Pairwise significance analysis (PAM) of the microarray 
indicated that five miR genes were significantly overexpressed in resistant 
NSCLC cells with a >1.5-fold change (Figure 8). These miRs were: miR-
222, miR-100, miR-221, miR-125b, miR-15b (Table 1). Three of these 
miRs, miR-222, miR-221, and miR-100, showed dramatic overexpression 
with 5- to 8-fold higher levels in resistant NSCLC cells compared with the 
sensitive NSCLC cells. Down-regulation occurred for only two miRs, miR-9 
and miR-96. 
To validate the microarray analysis, we performed quantitative Real-Time-
polymerase chain reaction (qRT-PCR) of the most overexpressed miRs 
(miR-222, miR-100, miR-221, miR-125b) and of down-regulated miR-9 in 
CALU-1 TRAIL-resistant cells, A459 and A549 semi-resistant cells and 
H460 TRAIL-sensitive cells. The analysis confirmed the results obtained by 
the microarray (Figure 9A).  
The expression of miR-222 in NSCLC cells was confirmed also with 
Northern blot (Figure 9B). 
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Figure 8  
Fold changes (resistant vs. sensitive) of the miRs present in NSCLC cells. The tree 
displays the log2 transformation of the average fold changes. Arrays were mean centered 
and normalized by using GENE CLUSTER 2.0. Average linkage clustering was 
performed by using uncensored correlation metric.  
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Figure 9 
(A) Real-time PCR of the most promising miRs targets obtained with microarray  
screening was performed by extracting RNA from the different NSCLC cells, as 
described in the methods section.  5 µg of RNA in 10 µl PCR reaction was used. TaqMan 
∆ct values were converted into absolute copy numbers using a standard curve from 
synthetic lin-4 miRNA. miRs 222, 100, 221,125b were markedly up-modulated in 
resistant but not in sensitive cell cultures, while miR-9  was markedly down-modulated. 
(B) Northern blot analysis of miR-222 expression. Ten micrograms of RNA were loaded 
onto a precast 15% denaturing polyacrylamide gel (Bio-Rad). RNA was then 
electrophoretically transferred to bright-Star blotting membranes and membrane 
incubated with labelled miR-222 probe. miR-222 was strongly up-regulated in TRAIL-
resistant CALU-1 cells.  
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Role of miR-221 and 222 in TRAIL resistance in NSCLC-  
In order to test the role of these overexpressed miRs in TRAIL sensitivity in 
lung cancer, we transfected H460 TRAIL-sensitive cells with pre-miR-221 
and -222. Increased expression of these miRs upon transfection was 
confirmed by Real-Time PCR (Figure 10A). Overexpression of miR-221 
and -222 in H460 cells made these cells more resistant to TRAIL-induced 
cell death by about 40% (Figure 10C). Interestingly, miR-100 also increased 
TRAIL resistance, while pre-miR-125b and control miR overexpression did 
not produce any effect (data not shown). A propidium iodide staining in 
H460 transfected with both pre-miR-221 and 222 confirmed these results 
(Figure 10E). 
Anti-miR inhibitors are sequence-specific and chemically modified to 
specifically target and knock down individual miR molecules. We 
transfected CALU-1 TRAIL-resistant cells with anti-miR inhibitor -221 and 
-222 and then assessed TRAIL sensitivity. As shown in Figure 10B, the 
levels of miR-221 and -222, assessed by RT-PCR, were reduced. 
Interestingly, the inhibition of miR-221 and 222 expression with the specific 
anti-miR inhibitor, was able to change the insensitive TRAIL phenotype to a 
sensitive one (Figure 10D). A scrambled non-specific anti-miR did not 
produce any effect. We also tested the effects of miRs 221 and 222 on the 
activation of caspase 8, 3 and PARP. Interestingly, while in H460 cells, 
TRAIL induced the activation of caspase cascade, as assessed by the 
appearance of the cleaved fragment, the co-incubation of TRAIL with 
222&221 premiR, induced a reduction of TRAIL-mediated cell death 
machinery activation (Figure 10F). TRAIL receptors expression was not 
affected by miR-221 and -222 up or down modulation (Figure 10G). 
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Figure 10 
(A) Real time PCR analysis after transfection of pre-miR221&222 in H460 cells. RNA 
was extracted and analyzed as previously described. miR transfection resulted in an 
increase of miR-221 and -222 expression in H460  
cells. (B) Real time-PCR analysis of miR-221&222  transfection in CALU-1 cells. Cells 
were transfected with 100 nmol of -221 or -222 anti-miR oligonucleotides. RNA was 
extracted and analyzed as previously described. Anti-miR transfection resulted in a 
decrease of miR-221&222 expression. (C) Cells were transfected either with control 
scrambled miR or with 100 nmol of pre-miR-221,-222 and -100. 24 hrs after transfection, 
cells were spitted into 96 well-plates and treated with 400 ng/ml of Super-Killer TRAIL 
for 24 hours. Cell viability was evaluated with the CellTiter Assay. miR-221&222 and 
miR-100 overexpression induced TRAIL resistance in H460 cells. (D) Effects of anti-
miRs on cell death. Cells were transfected with 100nM of anti-miRs 222, 221 or a 
scrambled control. 24 hrs after transfection, cells were split into 96 well and treated with 
400 ng/ml of Super-Killer TRAIL for 24 hrs, and cell viability was assessed as previously 
described. Down-regulation of miRs 221&222 in CALU-1 cells increased TRAIL 
sensitivity. (E) Propidium iodide (PI) staining of apoptotic cells- TRAIL was added for 
24 hours and cell death was evaluated by PI staining and FACS analysis. miR221&222 
overexpression induced TRAIL resistance in H460 cells. (F) The same cells (H460) were 
also assessed for caspase activation by Western blot. Eighty micrograms of total extract 
was loaded onto 10% SDS-PAGE. The membrane was blotted with anti caspase 8 
(1:1000), PARP (1:200), or caspase 3 (1:200) antibodies. Loading control was obtained 
using anti-β actin antibody. (G) Western blot anti-DR4 and DR5 after miRs transfection. 
H460 cells were transfected with 100nM of -221 and -222 while CALU cells were 
transfected with anti miR-221 and -222. Fifty micrograms of total extract was loaded 
onto 10% SDS-PAGE. The membrane was blotted with anti DR4, DR5 (1µg/ml) and 
DcR1 and DcR2 antibody (0.5 µg/ml). Loading control was obtained with anti-β actin 
antibody (1:5000). 
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miR-221 and -222 expression is repressed in TRAIL sensitive cells by 
epigenetic modifications- 
In disease, recent studies have shown that miRNA expression profiles are 
distinct between normal tissues and derived tumors (50) and between 
different  tumor types (49). Interestingly, down-regulation of subsets of 
miRNAs is a common finding in many of these studies (50, 51),suggesting 
that some of these miRNAs may act as putative tumor suppressor genes. 
This last indication has been studied in more detail for particular cases, and 
for example, the down-regulated let-7, miR-15/miR-16, and miR-127 target 
the oncogenic factors RAS, BCL-2, and BCL-6, respectively (21, 52, 53). 
One explanation is a failure at the posttranscriptional regulation of these 
miRNAs in cancer cells (54). However, additional mechanisms could also be 
invoked. Because the down-regulation of many relevant tumor suppressor 
genes in human cancer, such as hMLH1, BRCA1, and p16INK4a, has been 
tightly linked to the presence of CpG island promoter hypermethylation (55-
57), we wondered if the same mechanism could be playing a role in the 
described loss of miRNA expression in tumors. In this regard, restoration of 
miRNA-127 expression in cancer cells by treatment with a DNA-
demethylating agent has been recently reported (53). These recent and 
exciting data support the idea of an aberrant DNA methylation pattern of 
miRNA genomic loci in human tumors. 
 Histone deacetylase inhibitors (HDACis) are a promising new class of 
antineoplastic agents with the capacity to induce growth arrest and/or 
apoptosis of cancer cells. Furthermore, the down regulation of many relevant 
tumor suppressor genes in human cancer has been tightly linked to the 
presence of CpG island promoter hypermethylation (55, 57). Therefore, we 
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wondered whether the same mechanism could be playing a role in the loss of 
miR-221 and -222 expression in NSCLC cells.  
We treated TRAIL sensitive H460 cell line for 24 hrs with different 
concentrations of Trichostatin A (TSA), sodium butyrate or the DNA 
demethylating agent, 5' aza-cytidine (Aza), and evaluated miR-222 levels by 
northern blot (Figure 11 A-D). Interestingly, we observed a dose and time-
dependent effect of Aza, alone and combined with TSA treatment in the 
regulation of miR-222 expression levels. A comparable effect of HDACis or 
Aza was also observed in the regulation of miR-221 (Figure 11E). 
Based on the findings described above, we tested the effects of epigenetic 
modifications on TRAIL sensitivity in H460 cells. As shown in Figure 11F 
we found, that the sensitivity of H460 cells to TRAIL was reduced upon 
HDACi or Aza treatment, in accordance with the increase of miR-221 and -
222 expression. This effect was time-dependent and reached maximum level 
after coincubation with Aza (72hrs) and TSA (24 hrs). 
Our results suggest that epigenetic mechanisms contribute to the 
transcriptional down-regulation of miR-221&222 in human H460 TRAIL 
sensitive cells. and a treatment of 5-aza-dC and a histone deacetylase 
inhibitor, trichostatinA, increased TRAIL resistance by up-regulation of miR 
221&222. 
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Figure 11 
H460 cells were treated:  (A) for 24 hrs at different concentrations of 
trichostatin A (TSA) (100, 200, 300, and 500 nM); (B)  for 24 hrs with 
sodium butyrate (10, 25, 50, 75, and100 mM); (C) daily for 72 hrs with 5’-
Aza-2’-deoxycytidine (AZA) (1-5-10 mM; (D) for 24 hrs with 300nM of 
TSA or with 10mM 5’-AZA for 72hrs followed by 300nM TSA treatment 
for 24hrs. Cells were collected for RNA extraction.  Northern blot analysis 
were performed as described in the methods, using miR-222 as probe. RNA 
loading control is also shown (EtBr = etidium bromide). (E) Cells were 
incubated for 24 or 48 hrs with 10mM of AZA. Northern blot analysis was 
performed as described in the methods. miR-221 was used as probe. An 
oligonucleotide complementary to the U6 RNA was used for normalization 
of the expression levels in the different samples. (F) H460 cells were treated 
for 24-48-72 hrs with 10 µM  AZA or with 300 nM TSA  24 hrs or  with 
AZA for 72 hrs followed by TSA  for 24 hr in the presence of TRAIL. 
500.000 cells were then stained with FITC-conjugated annexin V antibody 
and propidium iodide (PI) and then subjected to flow cytometric analysis. 
miR221&222 overexpression, after AZA-TSA treatments, decreased  
TRAIL sensitivity in H460 cells. 
. 
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p27
Kip1
  and Kit expression in NSCLC 
We analyzed the predicted targets of the three most significantly 
overexpressed miRNAs (miR-222, miR-100, and miR-221) in TRAIL-
resistant cells. The analysis was performed with three public available 
algorithms to predict human miR gene targets, i.e., MIRANDA, 
TARGETSCAN and PICTAR.  In this study, we focused on miR-221 and -
222, which are located close to each other on the short arm of the X 
chromosome. The concordant expression pattern in NSCLC suggested 
shared regulatory mechanisms for the expression of these two clustered 
miRs. They are up-regulated in TRAIL-resistant NSCLC cells and may 
promote TRAIL resistance by blocking expression of key functional 
proteins.  
Different studies have demonstrated that both the pro-oncogene KIT and the 
tumor suppressor p27Kip1  are miR-221&222 targets (25, 58-60).  We thus 
investigated Kit and p27 Kip1 expression in NSCLC cells.  
Western blotting of NSCLC cells with a monoclonal anti-Kit antibody 
revealed two bands of ~140kDa and 120kDa, corresponding to the mature 
fully glycosylated and the partially glycosylated Kit isoform, respectively 
(61) (Figure 12A). Interestingly, Kit protein was markedly up-regulated in 
sensitive, and down regulated in resistant, NSCLC cells.  
FACS analysis, used for quantitative determination of cell surface Kit-
receptor expression with specific antibodies against human Kit receptors 
(Figure 12B), confirmed the western blot results. Kit was a target of miR-
221 and -222 in human NSCLC cells since its expression was up-regulated 
in CALU-1 cells upon anti-miR-222 transfection (Figure 12C). The p27kip1    
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gene is a member of the Cip/Kip family of cyclin-dependent kinase (CDK) 
inhibitors that function to negatively control cell cycle progression. 
It binds to CDK2 and cyclin E complexes to prevent cell cycle progression 
from G1 to S phase. p27kip1 also acts as a tumor suppressor and its expression 
is often distrupted in human cancers. 
Decreased p27kip1  levels have been correlated with tumor aggressiveness and 
poor patient survival (62, 63). 
The low levels of p27kip1 protein observed in many aggressive types of 
cancer are likely to be mediated by different mechanisms (62). 
The abundance of p27kip1 protein is largely controlled through a variety of 
post-transcriptional regulatory mechanisms (64, 65) among which are 
sequestration by ciclin D/CDK4 complexes, accelerated protein destruction 
and cytoplasmic retention (66) . 
However, several studies have indicated that genes controlling the stability 
of p27kip1 protein might not always account for its lower expression in 
cancer, and that  p27kip1 can also be regulated at the level of translation 
(67,68). 
We next analyzed p27 kip1 expression in NSCLC cells. Interestingly, western 
blot analysis showed that p27 kip1 is clearly detectable in H460 cells, is 
reduced in A459 and A549 cells, and  is very low or absent  in CALU-1 cells 
(Figure 12E).  Furthermore, as observed for Kit, the miR- 222 transfection 
resulted in an increase of p27
 kip1
 expression in CALU-1 cells (Figure 12D). 
A gene expression profiling in TRAIL-resistant and sensitive NSCLC cells, 
using oligonucleotide microarrays confirmed the down-regulation of Kit and 
p27
kip1
 in CALU-1 resistant NSCLC cells (data not shown).  
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Figure 12 
 (A) Proteins from CALU-1, A459, A549 and H460 cells were extracted with RIPA 
buffer. Fifty µg of sample extract were resolved on 7.5% SDS-PAGE and transferred to 
Hybond-C extra nitrocellulose. Membranes were incubated with anti-Kit primary 
antibody (0.2 µg/ml). Both surface and total Kit expression was higher in the H460 cells. 
(B) FACS  analysis of cell surface Kit expression. Cells were stained with primary anti-
human h-SCFR affinity purified goat IgG (1µg/ml) or mouse MAb 002 (Isotype control) 
followed by 10 µl of secondary antibody, Fluorescein conjugated goat F(ab’)2, as 
described in the methods section. % Gated: A459 (46%); A549(39%); H460(82%); Calu-
1(21%). (C-D) CALU-1 cells were transfected with 100 nmol of anti miR-221&222 for 
48 hours. Fifty micrograms of total extract was loaded onto 7.5-12% SDS-PAGE. The 
membrane was blotted with anti Kit (0.2 µg/ml) and anti p27 Kip1 (1µg/ml) antibodies 
Loading control was obtained with anti-β actin antibody (1:5000). Anti miR-221&222 
were able to increase Kit and p27 Kip1 expression. (E) p27Kip1 expression in NSCLC- Fifty 
micrograms of total extract was loaded onto 12% SDS-PAGE. The membrane was 
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blotted with anti-p27Kip1 (1µg/ml) antibody. Loading was controlled with an anti-β actin 
antibody (1:5000). 
 
 
Role of the miR221&222 targets, p27 kip1 and Kit, on TRAIL-mediated 
apoptosis  in NSCLC- To investigate whether p27 kip1 or Kit were involved 
in TRAIL resistance, we down-regulated these genes with specific siRNAs 
and then evaluated TRAIL sensitivity. Specific anti-Kit or anti-p27 Kip1 
siRNAs induced a reduction of endogenous expression of Kit or p27 kip1 
proteins by about 70% (Figure 13A and C). In order to evaluate the role of 
p27 kip1 in these cells, we measured survival after treatment with TRAIL. As 
shown in Figure 13B, anti-p27 kip1 siRNA transfection increased H460 cell 
resistance to TRAIL. Surprisingly, the treatment of H460 with the specific 
Kit siRNA did not induce resistance to TRAIL treatments in H460 cells but 
an increase in apoptotic cell death mediated by TRAIL treatment (Figure 
13D). Kit expression is under miR 221&222 control but it’s down regulation 
is not responsable to TRAIL resistance in H460 cells.  
 
Kit function was also investigated by interfering with its kinase activity by 
incubation of the cells with the drug Imatinib (Gleevec). H460 cells were 
incubated with 4µM Imatinib for 48h, and then treated with TRAIL 
(400ng/ml) for 3, 6, 12, 24 hrs. As a negative control, cells were  treated 
with TRAIL or Imatinib alone (Figure 13E). 
Imatinib-TRAIL co-treatment induced an increase of TRAIL sensitivity in 
H460 cells. The effect was evident after only 3hrs of co-incubation. Imatinib 
alone did not induce significant apoptosis in NSCLC. 
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Figure 13   
(A) H460 cells were cultured to 80% confluence and transiently transfected 
with anti-p27 Kip1 siRNA, a pool of 4 target specific 20-25 nt siRNA 
designed to knock down gene expression. Fifty micrograms of total extract 
was loaded onto 12% SDS-PAGE. Western blot was assessed as previously 
described. (B) Annexin V and propidium iodide (PI) staining of H460 cells 
after transfection with anti-p27 siRNA. Interfering with p27 expression 
increased TRAIL resistance in H460 cells. Mean ± SD of four independent 
experiments in duplicate (C) H460 cells were transiently transfected in p60 
plates using LIPOFECTAMINE 2000 with siKit RNA for 48 hours.  
Western blot of cells transfected using anti Kit antibody.  Anti-Kit siRNA 
induced a marked down-regulation of Kit expression in H460 cells. (D) 
Propidium iodide (PI) staining of apoptotic cells- TRAIL was added for 24 
hours and cell death was evaluated by PI staining and FACS analysis.  
Experiments were done twice in triplicate. Interfering with Kit expression 
increased TRAIL sensitivity in H460 cells (E) H460 cells were treated with 
4µM imatinib for 48hrs, and then TRAIL (400ng/ml) was added for 
3,6,12,24 hrs. As negative control cells were treated with TRAIL (400ng/ml) 
and Imatinib (4 µM) alone.  Cell viability assay was determined like 
previously described. A representative experiment of four independent 
experiments is presented. 
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DISCUSSION 
 
Apoptosis-based anti-cancer therapies are designed to achieve tumor 
eradication through the use of death-inducing molecules capable of 
activating the apoptotic program selectively in neoplastic cells. Due to its 
specific toxicity for malignant cells, recombinant forms of TRAIL are 
among the most promising apoptosis-based anti-tumor agents (69, 70). 
Therapy based on the use of agonistic TRAIL receptor antibodies are now in 
phase 2 clinical trial in different kinds of cancer, included NSCLC (71). 
However, in a number of patients, tumor cells evade death signals generated 
by drugs through the activation of effective anti-apoptotic mechanisms (72, 
73). The aim of the present study was to identify specific signatures as 
potential therapeutic targets for the TRAIL-resistant phenotype in non small 
cell lung carcinoma (NSCLC).  
 
For this purpose, we analyzed miRs expression profile in TRAIL-resistant 
(CALU-1) and semiresistant NSCLC cell lines (A459, A549), versus a 
TRAIL sensitive cell line (H460). We identified five miRs up-regulated in 
the resistant cell lines (miR-222,-100,-221,-125b and -15b) and between 
these we further analyzed four of them with the highest fold change (miR-
222,-100,-221 and -125b). This pattern was specific for NSCLC cells since 
we did not find the same pattern in breast cancer cells analyzed with the 
same array (data not shown). 
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Forced overexpression of the miR -222, -100 and -221, but not of miR-125b, 
in the sensitive H460 cells increased resistance to TRAIL in these cells, thus 
indicating that repression of their target proteins is implicated in causing 
TRAIL resistance. Kept together our results show that the sensitivity of a 
cancer cell to a defined external signal is dictated by the expression of a 
small number of microRNAs.  
It has recently described that miRNAs are under epigenetic control (74). The 
epigenetic silencing of these miRs modulate the activity of oncogenes (the 
cycline dependent kinase, CDK6) and tumor suppressor genes 
(retinoblastoma protein, Rb). In the present study we demonstrate that 
expression levels of at least two of these miRs, miR221&222, are 
maintained low in the TRAIL sensitive H460 cells by epigenetic 
modifications. Indeed, both demethyllating agents and HDACis upregulated 
the levels of miR221&222 in a dose- and time-dependent manner. On the 
other hand, several studies demonstrate that HDACis treatment enhances 
TRAIL sensitivity in a number of different cancers gaining importance as 
potential anticancer drugs (47, 75). A plausible explanation for this apparent 
discrepancy likely relies on the pleiotropic effects of these agents on gene 
expression.  
Further, in order to support the involvement of miR-mediated regulation of 
protein levels in TRAIL resistance, we investigated the potential protein 
targets of miRs identified in our screening. We focused on the two highly 
related miRs, miR-221 and -222, that recognize several predicted target 
genes involved in intracellular signaling (and cell death) and thus good 
candidate regulators of cell response to TRAIL. 
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Recent reports revealed that the receptor tyrosine kinase Kit and the cycline-
dependent kinase inhibitor, p27 kip1, are both miR-221 and -222 functional 
targets (25, 58-60). Here we demonstrate that silencing of p27 kip1, but not of 
Kit, increases TRAIL resistance. This result well support the implication of 
miR-221 and -222 in determining the resistant/sensitive phenotype in 
NSCLC cells, and indicate p27 kip1 among target proteins that contribute to 
maintain cell sensitivity to TRAIL-induced cell death. Imatinib (Gleevec) is 
a tyrosine kinase inhibitor that targets Kit, plated-derived growth factor 
receptors (PDGFRs), and c-Abl (76). Hamai et al. (77), described that 
Imatinib treatment of melanoma cells was able to enhance TRAIL-induced 
cell death. In good agreement, we show that Gleevec further increases 
TRAIL-induced apoptosis in the H460 cells as well as in the CALU-1 cell 
line that do not express Kit, likely acting on other tyrosine kinase targets. 
Taken together these results indicate that even though miR-221 and -222 
regulate the levels of both p27 kip1 and Kit proteins their effects on TRAIL 
sensitivity are mainly mediated by p27kip1. However, it seems plausible that 
silencing of other additional targets of miR-221 and -222 contribute to 
TRAIL resistance in NSCLC cells. 
miR-221 and 222-mediated down regulation of p27
kip1
has been implicated in 
maintaining a more aggressive cancer phenotype, thus indicating p27
kip1
 as 
bona fide tumor suppressor (26). p27kip1 is a member of cyclin-dependent 
kinases (cdk) inhibitory proteins with putative tumor suppressor functions 
(78).  More recently, p27kip1 has been described to play different roles 
depending on the cell type context and on its citosolyc or nuclear cellular 
localization (79, 80). The fuctions of p27kip1 in the apoptotic process remain 
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unclear. Adenovirus-mediated transient overexpression of p27
kip1
 was 
demonstrated to induce apoptosis in transfetected cells (81, 82). Other 
reports describe p27 as anti-apoptotic gene (83, 84).  Therefore, this suggests 
that the survival effects of p27
kip1
, are cell-type specific  and may be 
mediated by p27- effects on anti-apoptotic proteins expression (83, 85). 
Whether similar molecular mechanisms underlie the increase in TRAIL 
resistance upon silencing of p27
kip1
 remain to be further investigated. 
 
In conclusion, our results demonstrate for the first time that the intracellular 
levels of few miRs may modulate sensitivity of a cancer cell to a death 
receptor ligand with important implications in the design of new therapeutic 
agents.   
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Table 1 
 
 
has-miR-221 Xp11.3            5.9  
has-miR-125b 11q23-24            5.4  
has-miR-15b 3q26.1            3.6  
hasmiR96  7q32.2           0.5  
has-miR-9  1q23.1           0.072  
 
 
Table-1- All differentially expressed miRs have q <0.01 (false positive rate). 
T test p<0.05. These miRs were identified by PAM as predictor of NSCLC 
with the lowest misclassification error. All the miRs, except miR-9 and -96, 
are up-regulated in the TRAIL resistant cells compared to the TRAIL-
sensitive one. 
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